Vir Biotechnology (VIR) Capital Expenditures (2018 - 2026)

Vir Biotechnology's Capital Expenditures history runs 9 years deep, the most recent figure standing at $390000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 76.06% year-over-year to $390000.0; the TTM figure through Mar 2026 stood at $3.6 million (down 49.09% YoY), while the FY2025 annual figure was $4.8 million, down 33.82% from the prior year.
• Capital Expenditures came in at $390000.0 for Q1 2026 at Vir Biotechnology, up from $348000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $20.6 million in Q2 2022 to a low of $317000.0 in Q3 2025.
• A 5-year average of $6.0 million and a median of $2.5 million in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 4090.74% in 2022 and slumped 92.96% in 2024, its largest moves.
• Vir Biotechnology's Capital Expenditures stood at $12.6 million in 2022, then tumbled by 87.79% to $1.5 million in 2023, then grew by 29.97% to $2.0 million in 2024, then slumped by 82.56% to $348000.0 in 2025, then gained by 12.07% to $390000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $390000.0, $348000.0, and $317000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison